4 results
Primary objective:Part 1: To determine the safety, tolerability, and RP2D of a daily dosing schedule (induction) of GSK3745417 Part 2: To evaluate clinical efficacy following the daily dosing *induction* period of GSK3745417 in participants with…
Part 1PrimaryTo assess dose limiting toxicities (DLTs) of EDR to select an RP3D for the combination to be used in Part 2 of this study.Secondary• To evaluate the overall safety profile of EDR to select an RP3D for the combination to be used in Part…
Primary Objectives:- To estimate complete response rate, per pathology review committee (PRC), and its duration in CIS participantsSecondary Objectives:- To evaluate progression free survival, per pathologie review committee (PRC), for all…
Primary:• To compare the efficacy of elranatamab vs lenalidomide Secondary:- To compare the efficacy of elranatamab vs lenalidomide- To determine the safety and tolerability of elranatamab- To evaluate the PK of elranatamab- To evaluate the…